Skip to content

Evaluation of perioperative antimicrobial prophylaxis in paediatric cardiac surgery

Evaluation of perioperative antimicrobial prophylaxis in paediatric cardiac surgery - EvACHS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00031598
Enrollment
800
Registered
2024-03-13
Start date
2024-03-13
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Q24.9

Interventions

Group 1: Evaluation of the postoperative course against the background of the duration of use of perioperative antimicrobial prophylaxis in order to achieve the best clinical treatment outcome while m

Sponsors

Klinik für Angeborene Herzfehler und Pädiatrische Kardiologie
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Days to 18 Years

Inclusion criteria

Inclusion criteria: Children who have undergone heart surgery for a congenital heart defect and have received perioperative antimicrobial therapy.

Exclusion criteria

Exclusion criteria: No antimicrobial therapy.

Design outcomes

Primary

MeasureTime frame
Is there a correlation between the duration of PAbP and the need for secondary antimicrobial escalation or postoperative length of stay in hospital?

Secondary

MeasureTime frame
Is there evidence that patients benefit from a PAbP of more than 24 hours? Is there a correlation between the duration of invasive ventilation and the duration of PAbP? Is there a correlation between postoperative inflammatory parameters and secondary antimicrobial escalation? Does the PAbP duration correlate with the occurrence of postoperative wound infections, positive blood cultures or postoperative survival?

Countries

Germany

Contacts

Public ContactPhilipp Müller

Klinik für Angeborene Herzfehler und Pädiatrische Kardiologie

philip.mueller.zkj@uniklinik-freiburg.de076127043230

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026